glp 1 and dopamine GLP-1s Like Ozempic May Be a New Treatment for Addiction Glucagon-like peptide 1 receptor activation

Birth control can deliver estrogen and a progestin in ways that stabilize symptoms earlier in the perimenopause transition and support long-term bone health

Novo Nordisk asks FDA not to allow GLP-1 compounding Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs

Glucagon-like peptide-1 (GLP-1) is a hormone produced by the small intestine, which is responsible for triggering the pancreas to release insulin, blocking the secretion of another hormone called glucagon, slowing digestion, and making you feel full after eating

Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al

To improve or achieve remission of some obesity-related complications and lower risk for cardiovascular events, individuals with a BMI of 35 kg/m 2 may need to lose more weight (1025%)

Though GLP-1s impact is primarily felt in the downstream part of the value chain, the spillover effects of changed consumer behavior among a small but rapidly growing segment are hitting across the industry in varying degrees: For F&B brands focused on calorie-dense snacks, focus should be on product innovation for better for you lines